These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 29882202)

  • 1. Time in Therapeutic Range of Oral Vitamin K Antagonists in Hospitalized Elderly Patients.
    Lafarge L; Khayi F; Bel-Kamel A; Charhon N; Sarfati L; Falquet B; Ducher M; Bourguignon L
    Drugs Aging; 2018 Jun; 35(6):569-574. PubMed ID: 29882202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality control of oral anticoagulation with vitamin K antagonists in primary care patients in Poland: a multi-centre study.
    Sawicka-Powierza J; Buczkowski K; Chlabicz S; Gugnowski Z; Powierza K; Ołtarzewska AM
    Kardiol Pol; 2018; 76(4):764-769. PubMed ID: 29313558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina.
    Tajer C; Ceresetto J; Bottaro FJ; Martí A; Casey M;
    Clin Appl Thromb Hemost; 2017 Jul; 23(5):445-453. PubMed ID: 26739542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of vitamin K antagonist oral anticoagulation in 322 patients with atrial fibrillation - real-life data from a survey in Eastern Switzerland.
    Maeder MT; König T; Bogdanovic S; Schneider I; Eugster W; Ammann P; König M; Beer J; Rickli H
    Swiss Med Wkly; 2017; 147():w14503. PubMed ID: 29039622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation.
    Lip GYH; Haguenoer K; Saint-Etienne C; Fauchier L
    Chest; 2014 Sep; 146(3):719-726. PubMed ID: 24722973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Time in therapeutic range (TTR) and follow-up of patients on vitamin K antagonist: A cohort analysis].
    Valdelièvre E; Quéré I; Caré B; Laroche JP; Schved JF
    J Med Vasc; 2018 May; 43(3):155-162. PubMed ID: 29754725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is the time in therapeutic range using the ratio of tests equivalent to the Rosendaal method?
    Caldeira D; Cruz I; Morgado G; Stuart B; Gomes AC; Martins C; João I; Pereira H
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):972-6. PubMed ID: 26083988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A simple method to identify patients on long-term warfarin who may derive the most benefit from new oral anticoagulants.
    Carrier M; Kimpton M; Wells PS; Langlois N; Kherani S; Le Gal G
    Blood Coagul Fibrinolysis; 2014 Dec; 25(8):812-5. PubMed ID: 24914740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulation control among patients on vitamin K antagonists in nine countries in Sub-Saharan Africa.
    Mwita JC; Francis JM; Pillay C; Ogah OS; Goshu DY; Agyekum F; Musonda JM; James MC; Tefera E; Kabo T; Ditlhabolo KI; Ndlovu K; Ayodele AY; Mikomangwa WP; Chillo P; Damasceno A; Folson AA; Oyekunle A; Tebuka E; Kalokola F; Forrest K; Dunn H; Karaye K; Jean-Pierre FL; Oljira CF; Assefa T; Taiwo TS; Nwafor CE; Omole O; Anakwue R; Cohen K
    J Thromb Thrombolysis; 2024 Apr; 57(4):613-621. PubMed ID: 38478250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry.
    Haas S; Ten Cate H; Accetta G; Angchaisuksiri P; Bassand JP; Camm AJ; Corbalan R; Darius H; Fitzmaurice DA; Goldhaber SZ; Goto S; Jacobson B; Kayani G; Mantovani LG; Misselwitz F; Pieper K; Schellong SM; Stepinska J; Turpie AG; van Eickels M; Kakkar AK;
    PLoS One; 2016; 11(10):e0164076. PubMed ID: 27792741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of oral anticoagulation with vitamin K antagonists in 'real-world' patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry.
    Esteve-Pastor MA; Rivera-Caravaca JM; Roldán-Rabadán I; Roldán V; Muñiz J; Raña-Míguez P; Ruiz-Ortiz M; Cequier Á; Bertomeu-Martínez V; Badimón L; Anguita M; Lip GYH; Marín F;
    Europace; 2018 Sep; 20(9):1435-1441. PubMed ID: 29095971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in the quality of oral anticoagulation therapy with vitamin K antagonists in German GP practices - results of the cluster-randomized PICANT trial (Primary Care Management for Optimized Antithrombotic Treatment).
    Mertens C; Siebenhofer A; Berghold A; Pregartner G; Ulrich LR; Mergenthal K; Kemperdick B; Schulz-Rothe S; Rauck S; Harder S; Gerlach FM; Petersen JJ
    BMC Health Serv Res; 2019 Aug; 19(1):539. PubMed ID: 31370840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the mean time in the therapeutic INR range and the SAME-TT2R2 score in patients with atrial fibrillation and cognitive impairment.
    Gorzelak-Pabiś P; Zyzak S; Krewko Ł; Broncel M
    Pol Arch Med Wewn; 2016 Aug; 126(7-8):494-501. PubMed ID: 27511466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol.
    Rivera-Caravaca JM; Roldán V; Esteve-Pastor MA; Valdés M; Vicente V; Marín F; Lip GYH
    Clin Ther; 2018 Jan; 40(1):114-122. PubMed ID: 29275065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists.
    Ruiz-Ortiz M; Bertomeu V; Cequier Á; Marín F; Anguita M
    Thromb Haemost; 2015 Oct; 114(4):695-701. PubMed ID: 26054407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention.
    Zulkifly H; Lip GYH; Lane DA
    Int J Clin Pract; 2022; 2022():5951262. PubMed ID: 35685589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SAMe-TT2R2 Score in the Outpatient Anticoagulation Clinic to Predict Time in Therapeutic Range and Adverse Events.
    Pivatto Junior F; Scheffel RS; Ries L; Wolkind RR; Marobin R; Barkan SS; Amon LC; Biolo A
    Arq Bras Cardiol; 2017 Apr; 108(4):290-296. PubMed ID: 28538758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The HIPOGAIA study: Monitoring of oral anticoagulation with vitamin K antagonists in the municipality of Gaia.
    Guedes M; Rego C
    Rev Port Cardiol; 2016 Sep; 35(9):459-65. PubMed ID: 27503590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.
    Park YK; Lee MJ; Kim JH; Lee JS; Park RW; Kim GM; Chung CS; Lee KH; Kim JS; Lee SY; Bang OY
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1383-1390. PubMed ID: 28412319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. INR variability in atrial fibrillation: a risk model for cerebrovascular events.
    Amouyel P; Mismetti P; Langkilde LK; Jasso-Mosqueda G; Nelander K; Lamarque H
    Eur J Intern Med; 2009 Jan; 20(1):63-9. PubMed ID: 19237095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.